Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines, founded in Barcelona, Catalonia, Spain, in 1909. Specializing in biopharmaceuticals from human plasma, it ranks as the European leader and third largest worldwide, manufacturing essential therapies for immunology, infectious diseases, pulmonology, critical care, hematology, neurology, and hepatology. Key products include immunoglobulins for immunodeficiencies and neurological disorders, albumin for intensive care and liver disease, Factor VIII for hemophilia A, Alpha-1 for genetic emphysema, antithrombin for clotting deficiencies, and hyperimmune immunoglobulins for post-exposure prophylaxis against rabies and tetanus. Grifols operates over 390 plasma donation centers globally, 15 industrial facilities across seven countries, and employs more than 23,800 people serving 110 countries. It also leads in transfusion medicine with diagnostics, reagents, and devices, while supplying biological materials for life-science research and clinical trials. With a plasma fractionation capacity of 22 million liters annually, aiming for 26 million by 2026, and over 1,200 researchers in 12 R&D centers, Grifols drives innovation in plasma proteomics and recombinant antibodies. The company upholds high standards in quality, safety, and sustainability, contributing significantly to treating rare, chronic, and life-threatening conditions.